Laboratori d'Enginyeria de Proteïnes, Departament de Biologia, Universitat de Girona, Girona, Spain.
PLoS One. 2013;8(1):e54568. doi: 10.1371/journal.pone.0054568. Epub 2013 Jan 18.
Onconase® is a highly cytotoxic amphibian homolog of Ribonuclease A. Here, we describe the construction of circularly permuted Onconase® variants by connecting the N- and C-termini of this enzyme with amino acid residues that are recognized and cleaved by the human immunodeficiency virus protease. Uncleaved circularly permuted Onconase® variants are unusually stable, non-cytotoxic and can internalize in human T-lymphocyte Jurkat cells. The structure, stability and dynamics of an intact and a cleaved circularly permuted Onconase® variant were determined by Nuclear Magnetic Resonance spectroscopy and provide valuable insight into the changes in catalytic efficiency caused by the cleavage. The understanding of the structural environment and the dynamics of the activation process represents a first step toward the development of more effective drugs for the treatment of diseases related to pathogens expressing a specific protease. By taking advantage of the protease's activity to initiate a cytotoxic cascade, this approach is thought to be less susceptible to known resistance mechanisms.
Onconase® 是一种高度细胞毒性的两栖类核糖核酸酶 A 同系物。在这里,我们通过连接该酶的 N-末端和 C-末端,构建了环状排列的 Onconase® 变体,这些连接的氨基酸残基被人类免疫缺陷病毒蛋白酶识别和切割。未切割的环状排列的 Onconase® 变体异常稳定、无细胞毒性,并能在人 T 淋巴细胞 Jurkat 细胞中内化。通过核磁共振波谱法测定了完整和切割的环状排列的 Onconase® 变体的结构、稳定性和动力学,为切割引起的催化效率变化提供了有价值的见解。对激活过程的结构环境和动力学的理解是开发针对表达特定蛋白酶的病原体相关疾病的更有效药物的第一步。通过利用蛋白酶的活性来启动细胞毒性级联反应,这种方法被认为不太容易受到已知的耐药机制的影响。